Second quarter EBITDA improved by a marginal 0.5% year-on-year to Rs 1,895 crore. The margins were 25%.
Segment-wise, the Indian business generated Rs 3,146 crore, growing 7% YoY, with the company’s brand Foracort number 1 in the domestic market. The North American operations had revenues of $233 million Albuterol holds the top position in the overall US Albuterol MDI market with a 22% share.
Cipla’s North America business continued to see strong growth across key differentiated assets during the second quarter of FY26. Are Lanreotide product also gained market share, rising to 22% in the quarter.
The company has further strengthened its US portfolio by launching Filgrastimthe first biosimilar on the American market. In addition, Cipla’s manufacturing facility in Bommasandra, Bengaluru, was classified as VAI (Voluntary Action Indicated) by the US FDA during the quarter – a positive regulatory outcome in support of the US operations.
Looking ahead, Cipla plans to launch four major respiratory assets by calendar year 2026, including gAdvair in Q4 FY26, along with three peptide assets such as Liraglutide. Notably, three of these four respiratory products are submitted from Cipla’s U.S. manufacturing facilities, reducing regulatory risk and increasing supply reliability. The African segment recorded revenues of $134 million, up 5% year-on-year, with Cipla’s South African private market business growing 1.3x faster than market rates. The Emerging Markets and Europe segment delivered $110 million, registered 15% year-on-year growth and achieved the region’s highest-ever quarterly revenue. In branded prescriptions, Cipla maintained its second position in the overall chronic segment, with chronic mix improving to 61.8%. Major therapies such as urology, anti-diabetics, cardiac, anti-infectives and dermatology outpaced the market growth.
The commercial generics division posted strong growth during the quarter, supported by a broader product base. Cipla now has two brands with trailing twelve month (TTM) sales of over Rs 100 crore, and five brands with TTM sales between Rs 50 crore and Rs 100 crore. The company also launched six new products in the second quarter of FY26, including an introduction in the ortho care category to expand therapy coverage.
In consumer health, Cipla reported robust growth, with both anchor and transformed brands scaling up. The company continued its steady EBITDA growth trajectory, with flagship products Nicotex, OmnigelAnd Cipladine maintained their number 1 positions in the respective categories.
On Thursday, Cipla shares were trading marginally higher at Rs 1,582 on the NSE.
#Cipla #Results #Net #profit #grows #YoY #crore #turnover #increases